Acute intermittent porphyria-another approach to therapy

1. 1. Acute Intermittent Porphyria patients in early or acute attacks were treated with folic acid (30 mg/day) administered orally for not longer than 10 days. 2. 2. Both clinical and biochemical improvement immediately followed folic acid administration. 3. 3. This is a simple and short-term therap...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wider de Xifra, E.A., Batlle, A.M.d.C., Stella, A.M., Malamud, S.
Formato: JOUR
Materias:
aminolevulinic acid
folic acid
acute intermittent porphyria
blood and hemopoietic system
case report
drug therapy
drug urine level
porphyrin precursor
preliminary communication
therapy
urinary excretion
5-Aminolevulinate Synthetase
Acute Disease
Adult
Aminolevulinic Acid
Ammonia-Lyases
Case Report
Female
Folic Acid
Human
Male
Porphobilinogen
Porphobilinogen Synthase
Porphyria
Porphyrins
Support, Non-U.S. Gov't
Acceso en línea:http://hdl.handle.net/20.500.12110/paper_0020711X_v12_n5-6_p819_WiderdeXifra
Aporte de:
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires
id todo:paper_0020711X_v12_n5-6_p819_WiderdeXifra
record_format dspace
spelling todo:paper_0020711X_v12_n5-6_p819_WiderdeXifra2023-10-03T14:17:44Z Acute intermittent porphyria-another approach to therapy Wider de Xifra, E.A. Batlle, A.M.d.C. Stella, A.M. Malamud, S. aminolevulinic acid folic acid acute intermittent porphyria blood and hemopoietic system case report drug therapy drug urine level porphyrin precursor preliminary communication therapy urinary excretion 5-Aminolevulinate Synthetase Acute Disease Adult Aminolevulinic Acid Ammonia-Lyases Case Report Female Folic Acid Human Male Porphobilinogen Porphobilinogen Synthase Porphyria Porphyrins Support, Non-U.S. Gov't 1. 1. Acute Intermittent Porphyria patients in early or acute attacks were treated with folic acid (30 mg/day) administered orally for not longer than 10 days. 2. 2. Both clinical and biochemical improvement immediately followed folic acid administration. 3. 3. This is a simple and short-term therapy, which can be used either for treatment or prophylaxis. © 1980. Fil:Wider de Xifra, E.A. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Batlle, A.M.d.C. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_0020711X_v12_n5-6_p819_WiderdeXifra
institution Universidad de Buenos Aires
institution_str I-28
repository_str R-134
collection Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic aminolevulinic acid
folic acid
acute intermittent porphyria
blood and hemopoietic system
case report
drug therapy
drug urine level
porphyrin precursor
preliminary communication
therapy
urinary excretion
5-Aminolevulinate Synthetase
Acute Disease
Adult
Aminolevulinic Acid
Ammonia-Lyases
Case Report
Female
Folic Acid
Human
Male
Porphobilinogen
Porphobilinogen Synthase
Porphyria
Porphyrins
Support, Non-U.S. Gov't
spellingShingle aminolevulinic acid
folic acid
acute intermittent porphyria
blood and hemopoietic system
case report
drug therapy
drug urine level
porphyrin precursor
preliminary communication
therapy
urinary excretion
5-Aminolevulinate Synthetase
Acute Disease
Adult
Aminolevulinic Acid
Ammonia-Lyases
Case Report
Female
Folic Acid
Human
Male
Porphobilinogen
Porphobilinogen Synthase
Porphyria
Porphyrins
Support, Non-U.S. Gov't
Wider de Xifra, E.A.
Batlle, A.M.d.C.
Stella, A.M.
Malamud, S.
Acute intermittent porphyria-another approach to therapy
topic_facet aminolevulinic acid
folic acid
acute intermittent porphyria
blood and hemopoietic system
case report
drug therapy
drug urine level
porphyrin precursor
preliminary communication
therapy
urinary excretion
5-Aminolevulinate Synthetase
Acute Disease
Adult
Aminolevulinic Acid
Ammonia-Lyases
Case Report
Female
Folic Acid
Human
Male
Porphobilinogen
Porphobilinogen Synthase
Porphyria
Porphyrins
Support, Non-U.S. Gov't
description 1. 1. Acute Intermittent Porphyria patients in early or acute attacks were treated with folic acid (30 mg/day) administered orally for not longer than 10 days. 2. 2. Both clinical and biochemical improvement immediately followed folic acid administration. 3. 3. This is a simple and short-term therapy, which can be used either for treatment or prophylaxis. © 1980.
format JOUR
author Wider de Xifra, E.A.
Batlle, A.M.d.C.
Stella, A.M.
Malamud, S.
author_facet Wider de Xifra, E.A.
Batlle, A.M.d.C.
Stella, A.M.
Malamud, S.
author_sort Wider de Xifra, E.A.
title Acute intermittent porphyria-another approach to therapy
title_short Acute intermittent porphyria-another approach to therapy
title_full Acute intermittent porphyria-another approach to therapy
title_fullStr Acute intermittent porphyria-another approach to therapy
title_full_unstemmed Acute intermittent porphyria-another approach to therapy
title_sort acute intermittent porphyria-another approach to therapy
url http://hdl.handle.net/20.500.12110/paper_0020711X_v12_n5-6_p819_WiderdeXifra
work_keys_str_mv AT widerdexifraea acuteintermittentporphyriaanotherapproachtotherapy
AT batlleamdc acuteintermittentporphyriaanotherapproachtotherapy
AT stellaam acuteintermittentporphyriaanotherapproachtotherapy
AT malamuds acuteintermittentporphyriaanotherapproachtotherapy
_version_ 1807314643066028032

Ejemplares similares